Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with CardiomyopathyBusiness Wire • 08/03/22
Alnylam Ranks #1 on Fast Company's Fourth Annual List of the 100 Best Workplaces for InnovatorsBusiness Wire • 08/02/22
Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/28/22
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 07/28/22
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period ActivityBusiness Wire • 07/28/22
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal ObesityBusiness Wire • 07/27/22
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 PolyneuropathyBusiness Wire • 07/22/22
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial ResultsBusiness Wire • 07/18/22
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in AdultsBusiness Wire • 06/13/22
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA NephropathyBusiness Wire • 06/09/22
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic TissuesBusiness Wire • 06/02/22
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1Business Wire • 05/24/22
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational VutrisiranBusiness Wire • 05/23/22
Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22